FindMyKOL

Chaim Vanek, MD

Basic profile

Oregon Health & Science University

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPortland, OR · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Chaim Vanek is an Endocrinology/Metabolic physician affiliated with Oregon Health & Science University. OpenAlex indexes 18 publications with 339 citations (h-index 5).

Overview

Scholarship

indexed output and impact (OpenAlex)
18publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

339citations

Citations across these publications.

5h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Ascendis Pharma
    Program year20258 paymentsResearch
    $12,348
  • KYOWA KIRIN, INC.
    Program year20251 payment
    $110
  • Alexion Pharmaceuticals, Inc.
    Program year20251 payment
    $78
All 5 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    55.6%
    l-Thyroxine30.4%
    Levothyroxine Sodium77%Synthroid21%Tirosint3%
    Part D<11 patients
    Recombinant Human Growth Hormone7.1%
    Genotropin58%Omnitrope26%Nutropin Aq Nuspin9%Humatrope8%
    Part D<11 patients

    + 9 more classes in this area

  • Genitourinary & hormones

    20%
    Androgen10.8%
    Testosterone Cypionate69%Testosterone24%Androgel7%
    Part D<11 patients
    Estrogen6.1%
    Estradiol100%
    Part D≥26 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    10.8%
    Vitamin D3 Analog3.1%
    Calcitriol100%
    Part D≥15 patients
    Biguanide (metformin)3%
    Metformin Hcl80%Metformin Hcl Er20%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)73.5% facility · 26.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”